Samsara BioCapital LLC Acquires 1,688,889 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Samsara BioCapital LLC boosted its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 242.6% in the fourth quarter, HoldingsChannel reports. The firm owned 2,385,060 shares of the biotechnology company’s stock after purchasing an additional 1,688,889 shares during the quarter. Aclaris Therapeutics accounts for about 0.8% of Samsara BioCapital LLC’s holdings, making the stock its 22nd largest holding. Samsara BioCapital LLC’s holdings in Aclaris Therapeutics were worth $5,915,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of ACRS. ExodusPoint Capital Management LP bought a new position in Aclaris Therapeutics during the fourth quarter worth $26,000. Invesco Ltd. acquired a new position in shares of Aclaris Therapeutics during the fourth quarter valued at about $28,000. Commonwealth Equity Services LLC bought a new position in shares of Aclaris Therapeutics during the 4th quarter worth about $36,000. Alpine Global Management LLC acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at about $38,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at about $82,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Price Performance

Shares of ACRS opened at $1.33 on Wednesday. The stock’s fifty day moving average price is $1.52 and its two-hundred day moving average price is $2.24. Aclaris Therapeutics, Inc. has a 1 year low of $0.95 and a 1 year high of $5.17. The firm has a market cap of $144.01 million, a PE ratio of -2.56 and a beta of 0.53.

Analyst Upgrades and Downgrades

ACRS has been the topic of several recent research reports. Scotiabank began coverage on Aclaris Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target on the stock. Cantor Fitzgerald started coverage on Aclaris Therapeutics in a report on Tuesday, March 18th. They issued an “overweight” rating on the stock. Finally, StockNews.com downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 8th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.